Morgan Stanley Cuts Halozyme Therapeutics (NASDAQ:HALO) Price Target to $93.00

Halozyme Therapeutics (NASDAQ:HALO) had its price target cut by research analysts at Morgan Stanley from $96.00 to $93.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price indicates a potential upside of 27.85% from the company’s previous close.

A number of other research firms also recently commented on HALO. HC Wainwright boosted their target price on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Saturday, February 21st. Wells Fargo & Company boosted their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a report on Thursday, February 19th. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Finally, Weiss Ratings lowered shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Tuesday, February 24th. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Hold” and a consensus target price of $80.67.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO traded up $6.33 during midday trading on Tuesday, reaching $72.74. The company’s stock had a trading volume of 2,175,469 shares, compared to its average volume of 1,740,726. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89. The company has a 50 day moving average price of $65.68 and a 200 day moving average price of $68.57. Halozyme Therapeutics has a one year low of $47.50 and a one year high of $82.22. The company has a market cap of $8.62 billion, a price-to-earnings ratio of 29.22, a price-to-earnings-growth ratio of 0.26 and a beta of 0.89.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The business had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. During the same period in the previous year, the firm earned $1.11 EPS. The business’s revenue for the quarter was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities research analysts expect that Halozyme Therapeutics will post 7.68 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $63.48, for a total transaction of $103,155.00. Following the transaction, the director directly owned 38,498 shares of the company’s stock, valued at approximately $2,443,853.04. The trade was a 4.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $64.24, for a total transaction of $1,284,800.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at $49,322,187.20. The trade was a 2.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 90,482 shares of company stock valued at $6,073,942. Corporate insiders own 2.50% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Several large investors have recently added to or reduced their stakes in HALO. Empowered Funds LLC bought a new stake in Halozyme Therapeutics in the first quarter worth approximately $755,000. Acadian Asset Management LLC bought a new stake in Halozyme Therapeutics in the first quarter worth approximately $195,000. Hsbc Holdings PLC grew its position in Halozyme Therapeutics by 117.1% in the second quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after acquiring an additional 5,448 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 174 shares in the last quarter. Finally, Baird Financial Group Inc. grew its position in Halozyme Therapeutics by 6.2% in the second quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock worth $577,000 after acquiring an additional 650 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Halozyme beat first-quarter expectations on both revenue and earnings, with revenue up 42% year over year to about $377 million and EPS of $1.60 topping estimates. HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
• Positive Sentiment: The company also announced a new $1 billion share repurchase program and said it expects to buy back at least $400 million in 2026, signaling confidence in cash flow and future performance. HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
• Neutral Sentiment: Halozyme reiterated full-year 2026 guidance for revenue, adjusted EBITDA, and non-GAAP EPS, which suggests management remains confident but did not raise its outlook despite the beat. HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
• Negative Sentiment: Some third-party summaries highlighted that diluted EPS came in below certain estimates, even though revenue was strong, which may temper enthusiasm around the quarter. Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.